S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
S&P 500   5,253.05 (+0.09%)
DOW   39,778.57 (+0.05%)
QQQ   444.26 (-0.13%)
AAPL   171.75 (-0.90%)
MSFT   420.59 (-0.20%)
META   487.76 (-1.24%)
GOOGL   150.99 (+0.08%)
AMZN   180.23 (+0.22%)
TSLA   176.83 (-1.67%)
NVDA   904.20 (+0.19%)
NIO   4.52 (-3.21%)
AMD   180.34 (+0.42%)
BABA   72.47 (+1.23%)
T   17.65 (+0.57%)
F   13.22 (+1.23%)
MU   117.82 (-1.11%)
CGC   8.60 (-9.95%)
GE   175.08 (-2.80%)
DIS   122.45 (+1.22%)
AMC   3.67 (-15.44%)
PFE   27.93 (+0.54%)
PYPL   67.09 (+0.78%)
XOM   116.14 (+1.02%)
NASDAQ:OCX

OncoCyte (OCX) Stock Price, News & Analysis

$2.94
-0.04 (-1.34%)
(As of 01:42 PM ET)
Today's Range
$2.93
$2.95
50-Day Range
$2.85
$3.35
52-Week Range
$2.08
$7.40
Volume
16,061 shs
Average Volume
11,428 shs
Market Capitalization
$24.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.87

OncoCyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
31.1% Upside
$3.87 Price Target
Short Interest
Bearish
2.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of OncoCyte in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.58) to ($2.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

Medical Sector

850th out of 939 stocks

Diagnostic Substances Industry

12th out of 13 stocks

OCX stock logo

About OncoCyte Stock (NASDAQ:OCX)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OCX Stock Price History

OCX Stock News Headlines

OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com
StockNews.com Begins Coverage on OncoCyte (NASDAQ:OCX)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
OncoCyte Stock (NASDAQ:OCX), Short Interest Report
BTIG Reaffirms Their Hold Rating on OncoCyte (OCX)
Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
OncoCyte Corp OCX
Oncocyte Reports Third Quarter 2023 Financial Results
Oncocyte to Announce Third Quarter 2023 Financial Results
Oncocyte Reports Second Quarter 2023 Financial Results
See More Headlines
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
3/28/2024
Next Earnings (Estimated)
3/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:OCX
Employees
75
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.87
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+29.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-72,900,000.00
Net Margins
-3,923.58%
Pretax Margin
-1,427.20%

Debt

Sales & Book Value

Annual Sales
$960,000.00
Cash Flow
$0.88 per share
Book Value
$5.78 per share

Miscellaneous

Free Float
8,101,000
Market Cap
$24.61 million
Optionable
No Data
Beta
0.80
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Joshua Riggs (Age 41)
    President, CEO & Director
    Comp: $373.2k
  • Mr. James Liu (Age 28)
    Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
    Comp: $192.48k
  • Dr. Ekkehard Schutz M.D.
    Ph.D., Chief Science Officer
  • Mr. Peter Hong
    VP, General Counsel & Secretary
  • Mr. Yuh-Min Chiang Ph.D.
    Senior Vice President of R&D and Product Development
  • Ms. Sandra O'Donald
    Senior Vice President of Business Operations
  • Dr. Michael D. West Ph.D. (Age 71)
    Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.
  • Ms. Sara Riordan
    Director of Medical Education

OCX Stock Analysis - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCX shares.
View OCX analyst ratings
or view top-rated stocks.

What is OncoCyte's stock price target for 2024?

3 analysts have issued 12-month price objectives for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they expect the company's stock price to reach $3.87 in the next year. This suggests a possible upside of 31.1% from the stock's current price.
View analysts price targets for OCX
or view top-rated stocks among Wall Street analysts.

How have OCX shares performed in 2024?

OncoCyte's stock was trading at $2.50 at the start of the year. Since then, OCX shares have increased by 18.0% and is now trading at $2.95.
View the best growth stocks for 2024 here
.

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our OCX earnings forecast
.

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) released its quarterly earnings results on Tuesday, November, 9th. The company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.40) by $0.60. The company earned $0.98 million during the quarter, compared to analysts' expectations of $3.20 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%.

When did OncoCyte's stock split?

Shares of OncoCyte reverse split on the morning of Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).

Who are OncoCyte's major shareholders?

OncoCyte's stock is owned by many different institutional and retail investors. Top institutional shareholders include Pura Vida Investments LLC (7.11%), Vanguard Group Inc. (3.00%), Vanguard Group Inc. (3.00%), Defender Capital LLC. (0.87%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Pura Vida Investments, Llc and Ronald Asbury Andrews.
View institutional ownership trends
.

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners